2024
Randomized placebo-controlled, double-blind clinical trial of nanoemulsion curcumin in women with aromatase inhibitor-induced arthropathy: an Alliance/NCORP pilot trial
Lustberg M, Fan-Havard P, Wong F, Hill K, Phelps M, Herrera K, Tsai N, Synold T, Feng Y, Kalu C, Sedrak M, Yee L. Randomized placebo-controlled, double-blind clinical trial of nanoemulsion curcumin in women with aromatase inhibitor-induced arthropathy: an Alliance/NCORP pilot trial. Breast Cancer Research And Treatment 2024, 205: 61-73. PMID: 38280052, PMCID: PMC11062803, DOI: 10.1007/s10549-023-07223-4.Peer-Reviewed Original ResearchAI-induced arthralgiaBrief Pain Inventory-Short FormRandomized placebo-controlledPostmenopausal womenPlacebo-controlledBreast cancerDouble-blind pilot trialDouble-blind clinical trialGrip strengthReduced risk of recurrenceDiscontinuation of treatmentRisk of recurrenceGastrointestinal adverse effectsPilot trialPlasma curcuminInflammation-related conditionsPatient-reported outcome measuresSerum estradiolWell-toleratedEstrone levelsPurposeAromatase inhibitorsTreatment armsRandomized trialsT0-T3Study agents
2021
Changes in Inflammatory Markers and Correlations with Serum Polyunsaturated Fatty Acids In Postmenopausal Women With Breast Cancer Undergoing Chemotherapy
Zhang Z, Ormiston K, Weinhold K, Schnell P, Kopec R, Lustberg M, Orchard T. Changes in Inflammatory Markers and Correlations with Serum Polyunsaturated Fatty Acids In Postmenopausal Women With Breast Cancer Undergoing Chemotherapy. Journal Of The Academy Of Nutrition And Dietetics 2021, 121: a18. DOI: 10.1016/j.jand.2021.06.034.Peer-Reviewed Original ResearchChanges in Serum Fatty Acids and Inflammatory Markers in Postmenopausal Women With Breast Cancer Following Chemotherapy Treatment
Zhang Z, Ormiston K, Schnell P, Kopec R, Lustberg M, Orchard T. Changes in Serum Fatty Acids and Inflammatory Markers in Postmenopausal Women With Breast Cancer Following Chemotherapy Treatment. Current Developments In Nutrition 2021, 5: 5140290. PMCID: PMC8182042, DOI: 10.1093/cdn/nzab036_032.Peer-Reviewed Original ResearchSerum fatty acidsInflammatory markersInterleukin-6Breast cancerSerum cytokinesPostmenopausal breast cancer patientsSerum inflammatory markersBreast cancer survivorsBreast cancer patientsFatty acidsMethods Serum samplesTumor necrosis factorTotal monounsaturated FAsTotal monounsaturated fatty acidsEnzyme-linked immunoassaySerum FCytokine changesPostmenopausal womenInflammatory profileCancer survivorsInflammatory stateCancer patientsIL-8Chemotherapy treatmentNecrosis factorTreating Alpelisib-Induced Hyperglycemia with Very Low Carbohydrate Diets and Sodium-Glucose Co-Transporter 2 Inhibitors: A Case Series
Blow T, Hyde PN, Falcone JN, Neinstein A, Vasan N, Chitkara R, Hurd MA, Sardesai S, Lustberg MB, Flory JH, Volek JS, Goncalves MD. Treating Alpelisib-Induced Hyperglycemia with Very Low Carbohydrate Diets and Sodium-Glucose Co-Transporter 2 Inhibitors: A Case Series. Integrative Cancer Therapies 2021, 20: 15347354211032283. PMID: 34259084, PMCID: PMC8283040, DOI: 10.1177/15347354211032283.Peer-Reviewed Original ResearchConceptsAdvanced breast cancerSodium-glucose co-transporter-2 inhibitorsLow-carbohydrate dietCase seriesCarbohydrate dietHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Growth factor receptor 2Sodium-Glucose CoTransporter 2 inhibitorsTarget adverse effectsFactor receptor 2Postmenopausal womenTreatment delayPharmacologic interventionsBreast cancerDose reductionReceptor 2HyperglycemiaTreatment efficacyHormone receptorsAdverse effectsAlpelisibSelective phosphatidylinositolTherapy
2019
Inflammatory and Affective Responses to Acute Resistance Exercise of Varying Loads in Postmenopausal Women.
Fairman C, Lustberg M, Haynam M, Kimborowicz A, Bartels J, Lantz M, Johnson S, Maresh C, Kraemer W, Focht B. Inflammatory and Affective Responses to Acute Resistance Exercise of Varying Loads in Postmenopausal Women. Medicine & Science In Sports & Exercise 2019, 51: 881-881. DOI: 10.1249/01.mss.0000563132.59377.b8.Peer-Reviewed Original Research
2018
Dietary Long-Chain n-3 Fatty Acid Intake and Arthritis Risk in the Women’s Health Initiative
Krok-Schoen J, Brasky T, Hunt R, Rohan T, Baker T, Li W, Carbone L, Mackey R, Snetselaar L, Lustberg M, Neuhouser M. Dietary Long-Chain n-3 Fatty Acid Intake and Arthritis Risk in the Women’s Health Initiative. Journal Of The Academy Of Nutrition And Dietetics 2018, 118: 2057-2069. PMID: 29921541, PMCID: PMC6204099, DOI: 10.1016/j.jand.2018.04.005.Peer-Reviewed Original ResearchConceptsArthritis riskRA riskPostmenopausal womenWomen's Health Initiative Observational StudyHealth initiativesDietary long chain nClinical trial cohortProspective cohort studyFood frequency questionnairePrevalence of arthritisFatty acid intakeWomen's Health InitiativeCox regression modelAnti-inflammatory propertiesFatty acidsHistory of arthritisEvidence of benefitRheumatoid arthritis riskLong chain nArthritis outcomesCohort studyFrequency questionnaireHazard ratioIncident osteoarthritisTrial cohort
2017
Diet Quality, Inflammation, and Quality of Life in Breast Cancer Survivors: A Cross-Sectional Analysis of Pilot Study Data
Orchard T, Andridge R, Yee L, Lustberg M. Diet Quality, Inflammation, and Quality of Life in Breast Cancer Survivors: A Cross-Sectional Analysis of Pilot Study Data. Journal Of The Academy Of Nutrition And Dietetics 2017, 118: 578-588.e1. PMID: 29233615, PMCID: PMC5869134, DOI: 10.1016/j.jand.2017.09.024.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsBreast NeoplasmsCancer SurvivorsCross-Sectional StudiesDietDrug-Related Side Effects and Adverse ReactionsFemaleHumansInflammationInterleukin-17Interleukin-6Middle AgedPilot ProjectsPostmenopauseQuality of LifeReceptors, Tumor Necrosis Factor, Type IITreatment OutcomeConceptsBreast cancer survivorsBody mass indexQuality of lifeLower IL-6Cancer survivorsDiet qualityIL-6Breast cancerTNFR-2QOL measuresEndocrine receptor-positive breast cancerReceptor-positive breast cancerEarly-stage breast cancerMidwestern cancer centerModifiable lifestyle factorsSerum proinflammatory cytokinesCancer Therapy-BreastHealthy Eating IndexAromatase inhibitor treatmentCross-sectional analysisEndocrine subscaleOverall HEIPrior chemotherapyPostmenopausal womenPrimary therapy
2015
Healthy Eating Index Scores are Associated with Inflammatory Markers in Breast Cancer Survivors
Arnold K, Andridge R, Logan A, Yee L, Lustberg M, Orchard T. Healthy Eating Index Scores are Associated with Inflammatory Markers in Breast Cancer Survivors. The FASEB Journal 2015, 29 DOI: 10.1096/fasebj.29.1_supplement.lb267.Peer-Reviewed Original ResearchHealthy Eating Index 2010Breast cancer survivorsTumor necrosis factor alpha receptor 2Cancer survivorsHEI scoresDiet qualityInflammatory markersIL-17IL-6Breast cancerTNFR-2Randomized placebo-controlled pilot studyOmega-3 Fatty Acid SupplementationPlacebo-controlled pilot studyEarly-stage breast cancerHealthy Eating Index scoreHealthier diet qualityStage breast cancerLower IL-6Fatty acid supplementationAromatase inhibitor treatmentAI therapyChemotherapy statusPrior chemotherapyPostmenopausal women
2011
Phase II Trial of Neoadjuvant Exemestane in Combination With Celecoxib in Postmenopausal Women Who Have Breast Cancer
Lustberg M, Povoski S, Zhao W, Ziegler R, Sugimoto Y, Ruppert A, Lehman A, Shiels D, Mrozek E, Ramaswamy B, Layman R, Brueggemeier R, Shapiro C. Phase II Trial of Neoadjuvant Exemestane in Combination With Celecoxib in Postmenopausal Women Who Have Breast Cancer. Clinical Breast Cancer 2011, 11: 221-227. PMID: 21729671, PMCID: PMC3440773, DOI: 10.1016/j.clbc.2011.03.022.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAndrostadienesAntineoplastic AgentsBreast NeoplasmsCarcinoma, LobularCelecoxibCyclooxygenase 2Cyclooxygenase 2 InhibitorsDrug Therapy, CombinationFemaleFollow-Up StudiesHumansImmunoenzyme TechniquesLymphatic MetastasisMiddle AgedNeoadjuvant TherapyNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingPostmenopausePyrazolesReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneSulfonamidesSurvival RateTreatment OutcomeConceptsPathological complete responsePhase II trialEstrogen receptorKi-67Neoadjuvant exemestaneII trialPostmenopausal womenCOX-2Breast cancerDefinitive breast cancer surgeryCOX-2 inhibitor celecoxibSerious cardiac eventsAnti-tumor responseBreast cancer surgeryAddition of celecoxibCOX-2 expressionMajority of womenStable diseaseCardiac eventsPartial responseComplete responseCancer surgeryCore biopsyAromatase inhibitorsHER-2